The Fund invested in BioVercys 32,6M CHF = 35M UD$ and got perhaps 10%-15% (?) of the company. Today the market cap of ATH was US$16,38M, much less than it has cash and also much less than what the investment by the Fund was to get 10-15 % (?) of BioVercys.
I do not think the experts of the Fund made any big mistake when they evaluated the value of that company. I would expect the corresponding valuation when and if the Fund evaluates PBT2 and ATH as a possible investments.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $115.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1220509 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 1220500 | 3 |
View Market Depth
| Last trade - 09.22am 11/09/2025 (20 minute delay) ? |
| ATH (ASX) Chart |
Day chart unavailable